(Total Views: 158)
Posted On: 09/27/2018 11:45:47 AM
Post# of 87158
The news this morning is excellent, and this is what is happening right now because of the DEA decision. Can we be that far behind?
Biotech Rockets After Cannabis Drug Gets Lowest DEA Restriction
• ALLISON GATLIN
• 10:56 AM ET
GW Pharmaceuticals (GWPH) stock is flying Thursday after the Drug Enforcement Agency lifted the last hurdle preventing the biotech company from commercializing its cannabis drug, a seizure treatment.
In morning trading on the stock market today, GW stock jumped 9%, near 177.70, in high volume. Shares of biotech companies broadly rose a fraction.
The DEA decision moved GW's drug Epidiolex to a Schedule 5 drug. Under the DEA Schedule, a Schedule 5 drug is considered to have a lower potential for abuse. Marijuana and cannabis are still Schedule 1 drugs, which have no accepted medical use and a high potential for abuse.
Now, Chief Executive Justin Gover says GW expects to make Epidiolex available within the next six weeks . Epidiolex is a seizure treatment for Lennox-Gastaut syndrome and Dravet syndrome. It's the first cannabis drug that comes entirely from the plant to get Food and Drug Administration approval.
https://www.investors.com/news/technology/gw-...treatment/
Biotech Rockets After Cannabis Drug Gets Lowest DEA Restriction
• ALLISON GATLIN
• 10:56 AM ET
GW Pharmaceuticals (GWPH) stock is flying Thursday after the Drug Enforcement Agency lifted the last hurdle preventing the biotech company from commercializing its cannabis drug, a seizure treatment.
In morning trading on the stock market today, GW stock jumped 9%, near 177.70, in high volume. Shares of biotech companies broadly rose a fraction.
The DEA decision moved GW's drug Epidiolex to a Schedule 5 drug. Under the DEA Schedule, a Schedule 5 drug is considered to have a lower potential for abuse. Marijuana and cannabis are still Schedule 1 drugs, which have no accepted medical use and a high potential for abuse.
Now, Chief Executive Justin Gover says GW expects to make Epidiolex available within the next six weeks . Epidiolex is a seizure treatment for Lennox-Gastaut syndrome and Dravet syndrome. It's the first cannabis drug that comes entirely from the plant to get Food and Drug Administration approval.
https://www.investors.com/news/technology/gw-...treatment/
(1)
(0)
